Broj 7.


  1. Sokić D, Janković S, Vojvodić N, Racionalna terapija epilepsija, 2002.
  2. Pylvanen V, Knip M, Pakarinen A, et al. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia. 2002; 43(5):514–517.
  3. Herzog AG. Catamenial epilepsy: definition, prevalence, pathophysiology and treatment. Seizure. 2008;17(2):151–159.
  4. Duncan S, Read Cl, Brodie MJ. How common is catamenial epilespy? Epilepsia. 1993;34, 827-831.
  5. Kariyawasam SH, Mannapperuma U, Jayasuriya WJ, et al. Occurrence of menstrual cycle related seizure patterns among epileptic women attending the tertiary neurology clinics of the National Hospital of Sri Lanka. Epilepsy Res. 2009;84(2–3):257–262.
  6. Saalmann, Y. B, Kirkcaldie, M. T,Waldron, S, et al. Cellular distribution of the GABA- A receptor-modulating 3a-hydroxy, 5a-reduced pregnane steroids in the adult rat brain. J. Neuroendocrinol. 2007; 19, 272–284.
  7. Stein,D.G.,and Sayeed,I. Is progesterone worth consideration as a treatment for brain injury. Am.J. Roentgenol. 2010; 194, 20–22.
  8. Reddy D.S. and Rogawski M.A. Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself. J. Pharmacol.Exp.Ther. 2010; 295, 1241–1248.
  9. Herzog AG, Klein P, Ransil BJ. Three patterns of catamenial epilepsy. Epilepsia. 1997;38(10):1082–1088.
  10. Herzog AG, Fowler KM, Sperling MR, et al; Variation of seizure frequency with ovulatory status of menstrual cycles. Epilepsia. 2011;52(10):1843–1848.
  11. Herzog AG, Frye CA. Seizure exacerbation associated with inhibition of progesterone metabolism. Ann Neurol. 2003;53(3):390–391.
  12. Herzog,A.G. Hormonal therapies: progesterone. Neurotherapeutics 6, 2009; 383–391.
  13. Reddy D.S, and Rogawski M.A. Neurosteroids as endogenous regulators of seizure susceptibility and use in the treatment of epilepsy. Epilepsia 51. 2010; (Suppl.5),84.
  14. Lim LL, Foldvary N, Mascha E, Lee J. Acetazolamide in women with catamenial epilepsy. Epilepsia. 2001;42(6):746−749.
  15. Feely M, Gibson J. Intermittent clobazam for catamenial epilepsy: tolerance avoided. J Neurol Neurosurg Psychiatr 1984; 47, 1279-1282.
  16. Webber MP, Hauser WA, Ottmann R, et al. Fertility in persons with epilepsy: 1935–1974. Epilepsia. 1986;27:746-752.
  17. Morrell MJ, Guldner GT. Self-reported sexual function and sexual arousability in women with epilepsy. Epilepsia. 1996;37:1204–10.
  18. Duncan S, Blacklaw J, Beastall GH, Brodie MJ. Sexual function in women with epilepsy. Epilepsia. 1997;38:1074-1091.
  19. Quigg M, Smithson SD, Fowler KM, et al. Laterality and location influ¬ence catamenial seizure expression in women with partial epilepsy. Neurology. 2009;73(3):223–227.
  20. Morrell MJ, Guidice L, Flynn KL, et al. Predictors of ovulatory failure in women with epilepsy. Ann Neurol. 2002;52(6):704–711.
  21. Drislane FW, Coleman AE, Schomer DL, et al. Altered pulsatile secretion of luteinizing hormone in women with epilepsy. Neurology. 1994;44:306–10.
  22. Isojärvi JI, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med. 1993;329:1283-1388.
  23. Betts T, Yarrow H, Dutton N et al. A study of anticonvulsant medication on ovarian function in a group of women with epilepsy who have only ever taken one anticonvulsant compared with a group of women without epilepsy. Seizure. 2003; 12:323-329.
  24. Bauer J. Epilepsie, Schwangerschaft und Sexualität. Darmstadt, Germany: Steinkopff; 2005.
  25. Doose DR. al. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia. 2003;44:540-549.
  26. Harden CL, Leppik I. Optimizing therapy of seizures in women who use oral contraceptives. Neurology. 2006; 26(suppl 4):S56-S58.
  27. Pregnancy, epilepsy, and AEDs – Steinhoff Dialogues in Clinical Neuroscience – 2008. Vol 10 . No. 1 .
  28. Sabers A, Öhmann I, Christensen J, Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology. 2003;61:570-571.
  29. Sidhu J, Job S, Singh S, Philipson R. The pharmacokinetic and pharmacodynamic consequences of the coadministration of lamotrigine and a combined oral contraceptive in healthy female patients. Br J Clin Pharmacol. 2006;61:191-199.
  30. 30. Christensen J, Petrenaite V, Atterman J, et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia. 2007;48:484-489.
  31. O’Brien MD, Guillebaud J: Contraception for women with epilepsy. Epilepsia 2006; 47: 1419–22.
  32. Schwenkhagen AM, Stodieck SR: Which contraception for women with epilepsy. Seizure 2008; 17: 145–50.
  33. Yerby MS. Quality of life, epilepsy advances, and the evolving role of anticonvulsants in women with epilepsy. Neurology 2000;55:S21–S31.
  34. Sokić D, Janković S, Vojvodić N, Neurološka zdravstvena zaštita žena sa epilepsijom u trudnoći Trudnoća i epilepsija, 2002.
  35. Mawera G, M, Briggsa G.A, Bakerb R. and al. Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study; Seizure. 2010; 19(2): 112–119.
  36. Bell GS, Nashef L, Kendall S. et al.Information recalled by women taking antiepilpeptic drugs for epilepsy: a questionnaire study. Epilepsy Res. 2002;52, 139-146.
  37. Rosenberg IH. Folic acid and neural tube defects-time for action? N Eng J Med.1992; 327, 1875-1876.
  38. Cynthia L. Harden, PeterW. Kaplan et al. Management issues for women with epilepsy—Focus on pregnancy (an evidence-based review): I. Obstetrical complications and change in seizure frequency; Epilepsia, 2009; 50(5):1229–1236.
  39. Borthen I, Eide MG, Veiby G, et al. Complications during pregnancy in women with epilepsy: population-based cohort study; BJOG An International Journal of Obstetrics and Gynaecology. 2009; 1736-1742.
  40. Veiby G, Daltveit A, Engelsen Bernt, Gilhus NE. Prenancy, delivery and outcome for the child in maternal epilepsy. Epilepsia 2009.
  41. Kaplan PW, Norwitz ER, Ben-Menachem et al. Obstetric risks for women with epilepsy during pregnancy. Epilepsy Behav 2007;11:283–91.
  42. Yerbi MS, Cawthorn L. Mortality rates in infants of mothers with epilepsy. Ann Neurol.1994; 36, 330.
  43. Viinikainen K, Heinonen S, Eriksson K, et al. Community-based, prospective, controlled study of obstetric and neonatal outcome of 179 pregnancies in women with epilepsy. Epilepsia 2006;47:186–192.
  44. Richmond JR, Krishnamoorthy P, Andermann E, Benjamin A. Epilepsy and pregnancy: an obstetric perspective. Am J Obstet Gynecol 2004;190:371–379.
  45. Cornelissen M, Steegers-Theunissen R, Kollee L et al. Increased incidence of neonatal vitamin K deficiency resulting from the maternal anticonvulsant therapy. Am J Obstet Gynecol 1993; 168, 923-928.
  46. Kaaja E, Kaaja R. et al. Enzyme-inducing antiepileptic drugs in pregnancy and the risk of bleeding in the neonate, Neurology. 2002; 26;58(4):549-53.
  47. Bassi V, Yerby MS, Devinsky O. Neurological Complications of Pregnancy, 2nd ed. Philadelphia, Pa: Lippincott Williams & Williams; 2002:185-212.
  48. EURAP Study Group. Seizure control and treatment in pregnancy: observation from the EURAP epilepsy pregnancy registry. Neurology. 2006;66:354-360.
  49. Bardy AH, Hiilesmaa VK, Teramo KA. Effect of pregnancy on the electroencephalogram of epileptic women. Acta Neurol Scand. 1988;78:22-27.
  50. Nakken KO, Lillestølen KM, Taubøll E, et al. Epilepsy and pregnancy–drug use, seizure control, and complications. Tidsskr Nor Laegeforen. 2006;126:2507-2510.
  51. Endo S, Hagimoto H, Yamazawa H, et al. Statistics on deliveries of mothers with epilepsy at Yokohama City University Hospital. Epilepsia. 2004;45(suppl 8):S42-S47.
  52. Schmidt D. et al. Change of seizure frequency in pregnant epileptic women, J Neurol Neurosurg Psychiatry. 1983;46(8):751-5.
  53. Tomson T, Battino D. Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. Clin Pharmacokinet. 2007;46:209-219.
  54. Pennell PB, Peng L, Newport DJ, et al. Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology.2008;70:2130–2136.
  55. Harden CL, Pennell PB, Koppel BS, et al. Practice Parameter update: management issues for women with epilepsy–focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding. Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009;3:142–149.
  56. Tomson T, Battino D. Teratogenic effects of antiepileptic drugs. Lancet Neurol. 2012; 11:803–813.
  57. Tomson T, Battino D, Bonizzoni E, et al.Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011; 10:609–617.
  58. Morrow J,Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006; 77: 193–8.
  59. Patsalos PN, Antiepileptic drug pharmacogenetics. Ther.Drugs.Monit.2000; 22,127-130.
  60. Yerbi MS, Special consideration for women with epilepsy. Epilepsia 1987; 28 (Suppl3): S29-S36.
  61. John J.C, Epilepsy and women. Epilepsy. 2009; 417-22.
  62. Meador KJ, Baker GA, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med.2009; 360:1597–1605.
  63. Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management issues for women with epilepsy—focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009; 73: 133–41.
  64. Abbasi F, Krumholz A, Kittner SJ, Langenberg P. Effects of menopause on seizures in women with epilepsy. Epilepsia. 1999; 40(2):205–210.
  65. Erel T, Guralp O. Epilepsy and menopause. Arch Gynecol Obstet. 2011;284(3):749–755.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12

O časopisu Neurovesti

„Neurovesti“ predstavljaju elektronsku publikaciju Društva mladih neurologa Srbije sa besplatnim pristupom preko web-adrese, i dinamikom objavljivanja na mesečnom nivou.


Kalendar dešavanja
<< Jan 2022. >>
27 28 29 30 31 1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31 1 2 3 4 5 6
NOVO – Škola epilepsija – “Lečenje epilepsije vođeno etiologijom”